Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


More Troubles For Martin Shkreli – That Guy Drug Makers Despise

Executive Summary

Martin Shkreli, who is largely despised by the biopharmaceutical industry, may be in even deeper trouble than he thought, with prosecutors telling a judge on May 3 they are considering additional charges against the former drug company CEO, who already is facing seven criminal counts, including securities fraud. Turing Pharmaceuticals Inc., one of the firms Shkreli created and used to lead, also is up against a new lawsuit from Impax Laboratories Inc., which is claiming breach of contract involving the drug Daraprim, whose price was hiked by more than 5,000%.


Related Content

Amgen's Harper Says Repatha Is Priced Right
It Was Shkreli's Show, But Pharma Was On Trial
Shkreli's Price-Hike Brag: '$1bn Here We Come'
Generics 'Express Lane' Urged To Rival High-Priced Drugs
Shkreli's Ponzi Scheme Trifecta: Lies, Deceit And Greed
Shkreli Arrested On Securities Fraud; KaloBios Hit Hard
Merck CEO: Don't Judge All Pharma On Turing
Biotech Walloped On Clinton Drug Price Controls Threat


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts